(Q37193620)

18 August 2017

1 reference

title

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? (English)

1 reference

18 August 2017

0 references

angiogenesis inhibitor

1 reference

1 reference

Cristiana Sessa

1

1 reference

18 August 2017

Aymeric Guibal

series ordinal

2

1 reference

18 August 2017

Gianluca Del Conte

series ordinal

3

1 reference

18 August 2017

Curzio Rüegg

series ordinal

4

1 reference

18 August 2017

17 June 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

7

1 reference

18 August 2017

378-391

1 reference

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

High throughput proteome screening for biomarker detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC1150

1 reference

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Inhibitors of the mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Measuring the clinical response. What does it mean?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Bevacizumab in the management of solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Molecular pathways in renal cell carcinoma--rationale for targeted treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Biomarkers in cancer staging, prognosis and treatment selection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Surrogate markers in antiangiogenesis clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Biomarkers for monitoring antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Clinical implications of circulating angiogenic factors in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Genomics and proteomics approaches in understanding tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Genes expressed in human tumor endothelium

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Endostatin's antiangiogenic signaling network

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Proteomic study of human umbilical vein endothelial cells in culture

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Improved mass spectrometric proteomic profiling of the secretome of rat vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

The biologic basis of in vivo angiogenesis imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Imaging of angiogenesis: clinical techniques and novel imaging methods

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

How molecular imaging is speeding up antiangiogenic drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Quantitative assessment of regional cerebral blood flows by perfusion CT studies at low injection rates: a critical review of the underlying theoretical models.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

New technologies and directed agents for applications of cancer imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Imaging angiogenesis: applications and potential for drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Perfusion CT for the assessment of tumour vascularity: which protocol?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Retraction notice: Padhani A. PET imaging of tumour hypoxia, Cancer Imaging 2006; 6: s117-s121

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Molecular imaging of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1150

7 January 2021

Identifiers

DOI

10.1038/NCPONC1150

1 reference

18 August 2017

1 reference